医学
佐他莫司
经皮冠状动脉介入治疗
临床终点
内科学
心肌梗塞
支架
心脏病学
靶病变
冠状动脉疾病
西罗莫司
依维莫司
药物洗脱支架
临床试验
外科
作者
Do‐Yoon Kang,Jae‐Sik Jang,Mineok Chang,Cheol Hyun Lee,Pil Hyung Lee,Jung‐Min Ahn,Seung-Whan Lee,Young‐Hak Kim,Seong-Wook Park,Duk‐Woo Park,Seung‐Jung Park
出处
期刊:JACC: Asia
[Elsevier]
日期:2022-08-01
卷期号:2 (4): 446-456
标识
DOI:10.1016/j.jacasi.2022.02.009
摘要
Outcomes of percutaneous coronary intervention for diffuse long lesions remain relatively unfavorable. Prior clinical trials investigated the relative efficacy and safety of different types of drug-eluting stents (DES) in long lesions.This study sought to compare the relative performance of different types of DES for de novo long (≥25 mm) coronary artery lesions.Using a pooled analysis of individual data of 1,450 patients from 3 randomized clinical trials, we compared angiographic and clinical outcomes of 5 different types of DES: 224 patients with cobalt-chromium everolimus-eluting stents (EES), 255 with platinum-chromium EES, 250 with Resolute zotarolimus-eluting stents, 245 with biodegradable polymer biolimus-eluting stents, and 476 with first-generation sirolimus-eluting stents (SES). The primary endpoint was in-segment late lumen loss at 9 months.The primary endpoint was not significantly different between 4 second-generation DES and 1 first-generation SES (0.17 ± 0.41 mm in cobalt-chromium EES; 0.11 ± 0.37 in platinum-chromium EES: 0.14 ± 0.38 in Resolute zotarolimus-eluting stents; 0.14 ± 0.38 in biodegradable polymer biolimus-eluting stents; or 0.10 ± 0.37 in SES, respectively, overall P = 0.38). Also, there were no significant between-group differences with respect to death, myocardial infarction, target-vessel revascularization, or stent thrombosis at 12 months. In the multiple treatment propensity-score analysis, the risk of angiographic and clinical outcomes was also similar among several types of DES.In this patient-level pooled analysis, several second-generation DES showed similar angiographic and clinical outcomes in patients with de novo long coronary lesions. (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038; Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV [LONG-DES-IV]; NCT01186094; and Everolimus-eluting [PROMUS-ELEMENT] vs. Biolimus A9-Eluting [NOBORI] Stents for Long-Coronary Lesions [LONG-DES-V]; NCT01186120).
科研通智能强力驱动
Strongly Powered by AbleSci AI